Literature DB >> 9109509

Differential agonist regulation of the human kappa-opioid receptor.

A D Blake1, G Bot, S Li, J C Freeman, T Reisine.   

Abstract

Opiates are potent analgesics used clinically in the treatment of pain. A significant drawback to the chronic use and clinical effectiveness of opiates is the development of tolerance. To investigate the cellular mechanisms of tolerance, the cloned human kappa-opioid receptor was stably expressed in human embryonic kidney (HEK 293) cells, and the effects of opioid agonist treatment were examined. The receptor-expressing cells showed specific high-affinity membrane binding for a kappa-selective opioid, 3H-labeled (+)-(5alpha,7alpha,8beta)-N-methyl-N-[7-(1-pyrrolidiny l)-1-oxaspiro [4,5] dec-8-yl] benzeneacetamide ([3H]U69,593), and a nonselective opioid antagonist, [3H]diprenorphine. Pretreatment with pertussis toxin or guanosine 5'-O-(3-thiotriphosphate) reduced [3H]69,593 binding, indicating that the human K receptor coupled to G proteins of the Gi or Go families in HEK 293 cells. The receptor-mediated inhibition of adenylyl cyclase was abolished by pertussis toxin pretreatment and was blocked by a kappa-selective antagonist, norbinaltorphimine. A 3-h pretreatment with a kappa-selective agonist, (+/-)-trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl] benzeneacetamide (U50,488), caused receptor down-regulation, whereas no receptor down-regulation was found after levorphanol pretreatment. U50,488 or dynorphin A(1-17) pretreatments (3 h) desensitized the ability of U50,488 or dynorphin A(1-17) to inhibit cyclic AMP accumulation, as evidenced by a decrease in functional potency. Also, U50,488 pretreatment desensitized the ability of levorphanol to inhibit forskolin-stimulated cyclic AMP accumulation. In contrast, pretreatment of cells with either levorphanol or a potent nonselective opioid, etorphine, resulted in no apparent receptor desensitization. Taken together, these results demonstrate that the human kappa receptor is differentially regulated by selective and nonselective opioid agonists, with selective agonists able to desensitize the receptor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9109509     DOI: 10.1046/j.1471-4159.1997.68051846.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

1.  Effects of pharmacological preconditioning with U50488H on calcium homeostasis in rat ventricular myocytes subjected to metabolic inhibition and anoxia.

Authors:  J C S Ho; S Wu; K W L Kam; J S K Sham; T M Wong
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

Review 2.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

Review 3.  Levorphanol: the forgotten opioid.

Authors:  Eric Prommer
Journal:  Support Care Cancer       Date:  2006-10-13       Impact factor: 3.603

Review 4.  Molecular mechanisms of opioid receptor-dependent signaling and behavior.

Authors:  Ream Al-Hasani; Michael R Bruchas
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

5.  Recovery from mu-opioid receptor desensitization after chronic treatment with morphine and methadone.

Authors:  Nidia Quillinan; Elaine K Lau; Michael Virk; Mark von Zastrow; John T Williams
Journal:  J Neurosci       Date:  2011-03-23       Impact factor: 6.167

6.  Opioid receptors signaling network.

Authors:  Lathika Gopalakrishnan; Oishi Chatterjee; Namitha Ravishankar; Sneha Suresh; Rajesh Raju; Anita Mahadevan; T S Keshava Prasad
Journal:  J Cell Commun Signal       Date:  2021-11-01       Impact factor: 5.908

7.  Direct inhibition of arcuate proopiomelanocortin neurons: a potential mechanism for the orexigenic actions of dynorphin.

Authors:  Xiaobing Zhang; Anthony N van den Pol
Journal:  J Physiol       Date:  2013-01-14       Impact factor: 5.182

Review 8.  Opioid receptor desensitization: mechanisms and its link to tolerance.

Authors:  Stéphane Allouche; Florence Noble; Nicolas Marie
Journal:  Front Pharmacol       Date:  2014-12-18       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.